CAR19 + IL-15

CAR19 + IL-15 refers to chimeric antigen receptor (CAR) engineered immune cell therapies targeting CD19—primarily on B lymphocytes—combined with interleukin-15 (IL-15) activity to enhance cell persistence, proliferation, and anti-tumor effect. This approach exists in two principal configurations: - *Co-administration*, where a CD19-directed CAR (commonly a CAR-T or CAR-NK therapy) is given alongside exogenous IL-15 or an IL-15 agonist (e.g., NKTR-255), aiming to improve expansion and durability of the infused cells in vivo[1][6]. - *Cell-intrinsic expression*, where the CAR-expressing cell is also engineered to produce/secrete IL-15, or the IL-15/IL-15Rα complex, leading to enhanced autocrine/paracrine signaling, improved stem cell memory phenotype, persistence, cytotoxicity, and potential myeloid and immunosuppressive cell modulation[2][3][4][9]. These strategies are being investigated primarily for **relapsed/refractory B-cell malignancies**, including **B-cell acute lymphoblastic leukemia (B-ALL)** and **B-cell lymphomas**, to overcome relapse and lack of long-term efficacy seen with standard CAR19 therapies. Preclinical and early clinical studies indicate that **CAR19 + IL-15** leads to greater anti-tumor activity, reduced cell exhaustion, improved metabolic and proliferative profiles, and enhanced in vivo persistence of the therapeutic cells[2][3][6][9]. Some work also suggests a potential for safer allogeneic (“off-the-shelf”) CAR-NK products with engineered IL-15 due to lower rates of major toxicities such as cytokine release syndrome[5][7].

Other names

CD19 CAR T cell therapy with IL-15CD-19 CAR T cell therapy with IL-15CD 19 CAR T cell therapy with IL-15CAR19-IL15CAR-19-IL15CAR 19-IL15CAR.19-IL15